Skip to search boxSkip to navigationSkip to main content

Pidilizumab in the treatment of diffuse large B-cell lymphoma

*Corresponding author for this work
  • Northwestern University
Scholary Output:
Contribution to journal
Review article
Research
Peer-review

Abstract

<p>Introduction: The programmed death-1 (PD-1) immune checkpoint pathway is an emerging target in the treatment of hematologic malignancies. Pidilizumab is an mAb that binds to PD-1 and is a safe and well-tolerated therapy. Recent data have shown clinical activity utilizing this strategy in diffuse large B-cell lymphoma (DLBCL).Areas covered: The role of PD-1 expression in hematologic malignancies is explored. Recent clinical trials including the results of a Phase I trial in hematologic malignancies and a Phase II trial of pidilizumab following autologous hematopoietic stem-cell transplant (AHSCT) are reviewed.Expert opinion: We review data that suggest that PD-1 is a promising target in the treatment and management of DLBCL. Changes in immune subsets following administration of pidilizumab are felt to represent on-target responses. The improvement in progression-free survival (PFS) following AHSCT supports a response to therapy. Importantly, the improvement in PFS for patients with positive FDG-PET/CT following AHSCT indicating residual disease further supports direct activity of pidilizumab in DLBCL.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Review article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1361-1368 (8 pages)

Journal (Volume, Issue Number)

Expert Opinion on Biological Therapy (Volume 14, Issue 9)

Publication milestones

  • Published - 09/2014

Publication status

Published - 09/2014

ISSN

1471-2598

Publication IDs

  • Scopus: 84905816355
  • PubMed: 25056108

Publication metrics

Metrics

SciVal
FWCI
0.45
SciVal
Author count
2
SciVal
citations
16
SciVal
Paper percentile
77
Scopus
citations
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
50
Citation count
19